EP1709421A4 - Methodes de diagnostic et de pronostic de cancers d'origine epitheliale - Google Patents
Methodes de diagnostic et de pronostic de cancers d'origine epithelialeInfo
- Publication number
- EP1709421A4 EP1709421A4 EP05705399A EP05705399A EP1709421A4 EP 1709421 A4 EP1709421 A4 EP 1709421A4 EP 05705399 A EP05705399 A EP 05705399A EP 05705399 A EP05705399 A EP 05705399A EP 1709421 A4 EP1709421 A4 EP 1709421A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pronosis
- cancers
- diagnosis
- methods
- epithelial origin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53530604P | 2004-01-09 | 2004-01-09 | |
PCT/US2005/000714 WO2005071387A1 (fr) | 2004-01-09 | 2005-01-10 | Methodes de diagnostic et de pronostic de cancers d'origine epitheliale |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1709421A1 EP1709421A1 (fr) | 2006-10-11 |
EP1709421A4 true EP1709421A4 (fr) | 2008-08-13 |
EP1709421B1 EP1709421B1 (fr) | 2017-08-02 |
Family
ID=34806925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05705399.3A Not-in-force EP1709421B1 (fr) | 2004-01-09 | 2005-01-10 | Methodes de diagnostic et de pronostic de cancers d'origine epitheliale |
Country Status (7)
Country | Link |
---|---|
US (2) | US20160103131A1 (fr) |
EP (1) | EP1709421B1 (fr) |
JP (1) | JP4847873B2 (fr) |
CN (1) | CN1930461A (fr) |
AU (1) | AU2005207318B2 (fr) |
CA (1) | CA2552882C (fr) |
WO (1) | WO2005071387A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007051880A (ja) * | 2005-08-15 | 2007-03-01 | Tokyo Univ Of Science | 膵臓癌の検出方法、膵臓癌の診断キット |
EP1757940A1 (fr) * | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In-vitro méthode pour la diagnose et surveillance du carcinome cellulaire renal en utilisant MMP-7 comme biomarqueur humoral |
JP2009515556A (ja) * | 2005-11-16 | 2009-04-16 | チルドレンズ メディカル センター コーポレーション | 乳癌リスクを評価する方法 |
WO2008119882A2 (fr) * | 2007-03-30 | 2008-10-09 | Wallac Oy | Procédés de criblage |
US20090029372A1 (en) * | 2007-05-14 | 2009-01-29 | Kobenhavns Universitet | Adam12 as a biomarker for bladder cancer |
US8348856B1 (en) | 2008-12-16 | 2013-01-08 | Zanetta Malanowska-Stega | Simultaneous multiple method out-patient uterus biopsy device and method |
GB201121924D0 (en) * | 2011-12-20 | 2012-02-01 | Fahy Gurteen Labs Ltd | Detection of breast cancer |
US20150004253A1 (en) * | 2012-01-20 | 2015-01-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method for the prognosis of survival time of a patient suffering from a solid cancer |
US20160208016A1 (en) * | 2013-08-29 | 2016-07-21 | University Of Copenhagen | Anti-ADAM12 antibodies for the treatment of cancer |
DE102015115158B4 (de) * | 2015-09-09 | 2017-07-13 | Fresenius Medical Care Deutschland Gmbh | Verfahren und Kit zur Diagnose von epithelial-mesenchymaler Transition (EMT) des Peritoneums |
JP7303748B2 (ja) | 2016-12-09 | 2023-07-05 | マラノウスカ-ステガ,ザネッタ | ブラシ生検装置、キット及び方法 |
JP7398226B2 (ja) * | 2019-09-03 | 2023-12-14 | 浜松ホトニクス株式会社 | 大腸がん罹患のリスクを評価するための方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040072A2 (fr) * | 1996-04-19 | 1997-10-30 | The University Of Sheffield | Proteines adam et leur utilisation |
US20020081641A1 (en) * | 2000-10-13 | 2002-06-27 | Children's Medical Center Corporation | Non-invasive enzyme screen for tissue remodelling-associated conditions |
WO2002059377A2 (fr) * | 2001-01-24 | 2002-08-01 | Protein Design Labs | Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3602097A (en) | 1996-07-15 | 1998-02-09 | Regents Of The University Of California, The | Genes from 20q13 amplicon and their uses |
US20030124543A1 (en) | 1999-01-15 | 2003-07-03 | Stuart Susan G. | Breast cancer marker |
US6358683B1 (en) | 1999-06-03 | 2002-03-19 | The Regents Of The University Of California | Blood-based assays for breast cancer |
JP2004507211A (ja) * | 2000-03-03 | 2004-03-11 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Adamポリヌクレオチド、ポリペプチドおよび抗体 |
US20030148410A1 (en) * | 2001-12-10 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer |
-
2005
- 2005-01-10 CN CNA2005800072738A patent/CN1930461A/zh active Pending
- 2005-01-10 AU AU2005207318A patent/AU2005207318B2/en not_active Ceased
- 2005-01-10 CA CA2552882A patent/CA2552882C/fr active Active
- 2005-01-10 WO PCT/US2005/000714 patent/WO2005071387A1/fr active Application Filing
- 2005-01-10 JP JP2006549489A patent/JP4847873B2/ja active Active
- 2005-01-10 EP EP05705399.3A patent/EP1709421B1/fr not_active Not-in-force
-
2015
- 2015-05-04 US US14/703,154 patent/US20160103131A1/en not_active Abandoned
-
2017
- 2017-07-17 US US15/651,120 patent/US20180156808A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040072A2 (fr) * | 1996-04-19 | 1997-10-30 | The University Of Sheffield | Proteines adam et leur utilisation |
US20020081641A1 (en) * | 2000-10-13 | 2002-06-27 | Children's Medical Center Corporation | Non-invasive enzyme screen for tissue remodelling-associated conditions |
WO2002059377A2 (fr) * | 2001-01-24 | 2002-08-01 | Protein Design Labs | Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein |
Non-Patent Citations (2)
Title |
---|
LE PABIC H. ET AL.: "ADAM12 in human liver cancers: TGF-b-regulated expression in stellate cells is associated with matrix remodeling", HEPATOLOGY, vol. 37, no. 5, May 2003 (2003-05-01), pages 1056 - 1066, XP002486182 * |
See also references of WO2005071387A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20180156808A1 (en) | 2018-06-07 |
AU2005207318B2 (en) | 2012-02-02 |
AU2005207318A1 (en) | 2005-08-04 |
JP2007519903A (ja) | 2007-07-19 |
CA2552882A1 (fr) | 2005-08-04 |
EP1709421B1 (fr) | 2017-08-02 |
WO2005071387A1 (fr) | 2005-08-04 |
EP1709421A1 (fr) | 2006-10-11 |
US20160103131A1 (en) | 2016-04-14 |
CN1930461A (zh) | 2007-03-14 |
CA2552882C (fr) | 2014-08-19 |
JP4847873B2 (ja) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1709421A4 (fr) | Methodes de diagnostic et de pronostic de cancers d'origine epitheliale | |
ZA200805741B (en) | Anti-MN antibodies and methods of using same | |
EP2041574A4 (fr) | Biomarqueurs du cancer et méthodes d'utilisation | |
GB2439497B (en) | Stroboscopic liberation and methods of use | |
IL189080A0 (en) | Substituted benzimidazoles and methods of preparation | |
EP1869224A4 (fr) | Marqueurs de méthylation pour le diagnostic et le traitement de cancers | |
ZA200710173B (en) | Tygecycline and methods of preparing 9-nitrominocycline | |
EP1812031A4 (fr) | Compositions et procedes de modification de biomolecules | |
IL180601A0 (en) | Methods and compositions for the detection of ovarian cancer | |
EP1913112A4 (fr) | Agent de soutenement et procedes d'utilisation | |
IL178593A (en) | Specific antibodies of fcγriib and methods for their use | |
HK1194395A1 (zh) | 抗體及其製備和使用方法 | |
EP2007307A4 (fr) | Procedes et trousses pour la detection de caries a un stade precoce | |
TWI367326B (en) | Wnt proteins and detection and treatment of cancer | |
EP1805519A4 (fr) | Protéines wnt et détection et traitement du cancer | |
EP1891407A4 (fr) | Dispositifs d'acceleration et procedes d'utilisation correspondants | |
EP2331711A4 (fr) | Procédés pour diagnostiquer le cancer et déterminer la survie globale et la survie sans maladie des patients atteints du cancer | |
GB0701498D0 (en) | System and method for enhanced measurement of rheological properties | |
EP1946007A4 (fr) | Derives de l'androsterone et leur procede d'utilisation | |
GB0417740D0 (en) | Methods and kit for the prognosis of breast cancer | |
EP2052054A4 (fr) | Antioxydants et procédés de fabrication d'antioxydants | |
IL192143A0 (en) | Alumina particles and methods of making the same | |
GB0400976D0 (en) | Methods of diagnosis | |
EP1856279A4 (fr) | Procédé de diagnostic du cancer du sein et compositions à cet effet | |
ZA200808600B (en) | Methods and compositions for the detection and treatment of cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060807 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MOSES, MARSHA, A. Inventor name: ROY, ROOPALI |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101ALI20080702BHEP Ipc: C07K 16/00 20060101ALI20080702BHEP Ipc: C07K 17/00 20060101ALI20080702BHEP Ipc: C07K 14/00 20060101ALI20080702BHEP Ipc: C07K 1/00 20060101ALI20080702BHEP Ipc: G01N 33/48 20060101ALI20080702BHEP Ipc: G01N 1/00 20060101AFI20050808BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080715 |
|
17Q | First examination report despatched |
Effective date: 20081201 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602005052446 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: G01N0001000000 Ipc: G01N0033574000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101AFI20170109BHEP |
|
INTG | Intention to grant announced |
Effective date: 20170215 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 915044 Country of ref document: AT Kind code of ref document: T Effective date: 20170815 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602005052446 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20170802 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 915044 Country of ref document: AT Kind code of ref document: T Effective date: 20170802 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171202 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171102 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602005052446 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
26N | No opposition filed |
Effective date: 20180503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180110 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180131 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180131 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20050110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170802 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20220127 Year of fee payment: 18 Ref country code: DE Payment date: 20220127 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20220125 Year of fee payment: 18 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230523 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602005052446 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230110 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230131 |